InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,446.68
(
-1.37%
)
US TECH 100
18,282.40
(
-2.97%
)
Dow Jones
40,347.97
(
-1.21%
)
Brent Oil
79.91
(
-0.08%
)
Bitcoin
64,454.78
(
-1.37%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

bladerunner1717

Send PM Follow Ignore
Followers 38
Posts 5652
Boards Moderated 0
Alias Born 11/09/2003

bladerunner1717

Re: biotech_researcher post# 4458

Wednesday, 12/29/2010 6:56:50 PM

Wednesday, December 29, 2010 6:56:50 PM

Post# of 80490
BTR,

If I were MRK, I get the checkbook out now. If Rida succeeds in sarcoma and IF it starts to show efficacy in solid tumors, then Berger's price will be off the charts. PGS knows something about mTor, so maybe he can comment. I think he mentioned somewhere that he has seen mTor efficacy in cardiology.

I agree with with "Aria" that MRK is the most logical partner. Pona gives them a competitive drug for BMY and NVS. And the ALK inhibitor gives them a competitive drug against PFE.

But who said these things were logical?


Bladerunner

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up